Literature DB >> 8728633

Severe lumbar lordosis after dorsal rhizotomy.

K Crawford1, L A Karol, J A Herring.   

Abstract

Two children with spastic quadriplegia who developed excessive lumbar lordosis after selective dorsal rhizotomy are described. The rhizotomy did not change the ambulatory status of either child (one nonambulator, one household ambulator). Preservation of unopposed hip flexion in the presence of multiple laminectomies may lead to the development of a lordotic deformity in children who sit most of the time. Excessive lumbar lordosis may cause pain and difficulty in sitting. Surgical correction of this deformity is complex because of the removal of posterior elements during the rhizotomy.

Entities:  

Mesh:

Year:  1996        PMID: 8728633     DOI: 10.1097/00004694-199605000-00008

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  5 in total

Review 1.  Lumbosacral Dorsal Rhizotomy for Spastic Cerebral Palsy: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-07-06

2.  Slow correction of severe spastic hyperlordosis in an adult by means of magnetically expandable rods.

Authors:  Christof Birkenmaier; Melvin D'Anastasi; Bernd Wegener; Carolin Melcher
Journal:  Eur Spine J       Date:  2017-11-22       Impact factor: 3.134

3.  Cerebral Palsy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-03       Impact factor: 3.972

Review 4.  Long-term effects of selective dorsal rhizotomy in children with cerebral palsy: a systematic review.

Authors:  Kristina Tedroff; Gunnar Hägglund; Freeman Miller
Journal:  Dev Med Child Neurol       Date:  2019-07-24       Impact factor: 5.449

5.  Surgical treatment for lumbar hyperlordosis after resection of a spinal lipoma associated with spina bifida: A case report.

Authors:  Tatsuya Sato; Ikuho Yonezawa; Shingo Onda; Kei Yoshikawa; Hiromitsu Takano; Yukitoshi Shimamura; Takatoshi Okuda; Kazuo Kaneko
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.